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Abstract
Introduction: There is an unmet clinical need for biomarkers to identify breast cancer patients at an increased risk
of developing brain metastases. The objective is to identify gene signatures and biological pathways associated
with human epidermal growth factor receptor 2-positive (HER2+) brain metastasis.
Methods: We combined laser capture microdissection and gene expression microarrays to analyze malignant
epithelium from HER2+ breast cancer brain metastases with that from HER2+ nonmetastatic primary tumors.
Differential gene expression was performed including gene set enrichment analysis (GSEA) using publicly available
breast cancer gene expression data sets.
Results: In a cohort of HER2+ breast cancer brain metastases, we identified a gene expression signature that
anti-correlates with overexpression of BRCA1. Sequence analysis of the HER2+ brain metastases revealed no
pathogenic mutations of BRCA1, and therefore the aforementioned signature was designated BRCA1 Deficient-Like
(BD-L). Evaluation of an independent cohort of breast cancer metastases demonstrated that BD-L values are significantly
higher in brain metastases as compared to other metastatic sites. Although the BD-L signature is present in all subtypes
of breast cancer, it is significantly higher in BRCA1 mutant primary tumors as compared with sporadic breast tumors.
Additionally, BD-L signature values are significantly higher in HER2-/ER- primary tumors as compared with HER2+/ER +
and HER2-/ER+tumors. The BD-L signature correlates with breast cancer cell line pharmacologic response to a
combination of poly (ADP-ribose) polymerase (PARP) inhibitor and temozolomide, and the signature outperformed
four published gene signatures of BRCA1/2 deficiency.
Conclusions: A BD-L signature is enriched in HER2+ breast cancer brain metastases without pathogenic BRCA1
mutations. Unexpectedly, elevated BD-L values are found in a subset of primary tumors across all breast cancer
subtypes. Evaluation of pharmacological sensitivity in breast cancer cell lines representing all breast cancer subtypes
suggests the BD-L signature may serve as a biomarker to identify sporadic breast cancer patients who might
benefit from a therapeutic combination of PARP inhibitor and temozolomide and may be indicative of a
dysfunctional BRCA1-associated pathway.
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Central nervous system metastases are diagnosed in ap-
proximately 10% to 16% of women with advanced breast
cancer [1,2]. The total incidence of brain metastases is
potentially higher than currently reported statistics, as
most brain metastases are diagnosed in response to clin-
ical symptoms rather than by an initial detection. Several
risk factors have been associated with the development
of brain lesions in patients with metastatic breast cancer
(MBC), including a younger age [3], having more than
two metastatic sites at diagnosis [3], negative estrogen
receptor (ER) status [1,4,5], human epidermal growth fac-
tor receptor 2-positive (HER2+) disease [1,4], and BRCA1/
2 mutation [6-8]. Survival for breast cancer patients with
brain metastases is poor, with a one-year survival probabil-
ity of approximately 20% [2]. These statistics highlight the
crucial need to develop biomarkers for the prediction of
brain metastasis risk and to identify the underlying bio-
logical pathways that promote brain metastasis for the de-
velopment of potential targeted therapeutics.
Patients with HER2+ MBC tumors are two to four
times more likely to develop brain metastases than pa-
tients with HER2-negative disease [1,4]. While systemic
trastuzumab has proven efficacious for treating aggres-
sive HER2+ breast cancer, its use has been associated
with the central nervous system as the first site of re-
lapse [9]. Thus, there is an urgent clinical need for bio-
markers to identify patients at higher risk of developing
brain metastases, as well as to identify alternative thera-
peutic approaches. In this study, we aim to identify gene
signatures associated with HER2+ brain metastases for
potential biomarker development as well as to provide
insight into the underlying associated biological pathways.
Materials and methods
Patients and clinical samples
Patient and primary tumor characteristics are presented
in Additional file 1. The HER2 status was assessed by
HER2 immunohistochemistry (IHC) and/or gene ampli-
fication, and tumor grading was determined as described
previously [10]. The breast cancer brain metastatic spec-
imens consisted of fresh frozen biopsies obtained from
the MD Anderson Cancer Center between 1998 and
2001; in all 19 cases the brain was the first site of re-
lapse. As patient-matched primary breast tumor speci-
mens were not available for these brain metastatic samples,
we obtained HER2+ primary breast cancer specimens from
Massachusetts General Hospital; these samples were ob-
tained from patients with either no relapse or relapse to
sites other than the central nervous system and consisted
of fresh frozen biopsies obtained between 1998 and 2006.
These breast cancer brain metastatic specimens and breast
tumors were matched for patient age upon primary tumor
detection and the ER status of the primary tumor. Patient
consent was obtained for study participation and the study
was approved by the human research committees of the
MD Anderson Cancer Center and the Massachusetts
G e n e r a lH o s p i t a li na c c o r d a nce with the National In-
stitutes of Health human research study guidelines.
Laser capture microdissection, RNA extraction, and
microarray hybridization
RNA was isolated from a highly enriched population of
4,000 to 5,000 malignant epithelial cells procured by laser
capture microdissection and was hybridized to Affymetrix
X3P GeneChips (Affymetrix, Santa Clara, CA, USA) as
previously described [11]. The data was deposited in the
National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus (GEO) [12] and are accessible
through GEO Series accession number GSE43837 [13].
Gene set enrichment analysis
Computation of gene expression was done using the
MAS5 algorithm as implemented in the call.expers
function in version 2.14.05 of the simpleaffy package of
Bioconductor [14]. Gene set enrichment analysis (GSEA)
analysis was performed using version 2.0 of GSEA run on
all the gene sets in version 2.5 of the Molecular Signatures
Database (MSigDB) [15].
Calculation of BRCA1 Deficient-Like metagene value
All the genes in the BRCA1_OVEREXP_DN gene set,
which was experimentally derived as described [16], in
version 2.5 of the MSigDB [17] were mapped as de-
scribed below to microarray identifiers. The gene expres-
sion values for all those identifiers were then averaged to
form the BRCA1 Deficient-Like (BD-L) metagene. Specific
probes measured are indicated in Additional file 1 for each
figure.
Mapping gene symbols to microarray identifiers
Gene symbols were mapped to Entrez GeneIDs using
the 2 February 2008 version of the gene information file
from ftp.ncbi.nlm.nih.gov/gene/DATA. First the ‘Symbol’
column was searched and, if that failed, the ‘Synonyms’
column was searched. To map an Entrez GeneID to
Affymetrix HG-U133A probe set identifiers, version na24
of the annotation file from the Affymetrix website was
used. The ‘Entrez Gene’ column of that annotation file
was augmented by trying to fill empty entries by using the
corresponding entries in the ‘UniGene ID’ and ‘Represen-
tative Public ID’ columns to search the file Hs.data from
build 209 of Unigene and the 2 February 2008 version of
the gene2accession file from ftp.ncbi.nlm.nih.gov/gene/
DATA. An Entrez GeneID was then mapped to every
probe set identifier that had the Entrez GeneID in the
augmented ‘Entrez Gene’ column. To map Entrez Gen-
eIDs to Rosetta spot IDs, we used [18] (downloaded 2
McMullin et al. Breast Cancer Research 2014, 16:R25 Page 2 of 10
http://breast-cancer-research.com/content/16/2/R25February 2008), the file Hs.data from build 209 of Uni-
gene and the 2 February 2008 version of the gene2ac-
cession file from ftp.ncbi.nlm.nih.gov/gene/DATA.
Sequencing of genomic BRCA1
All 22 coding exons of the BRCA1 (NM_007294.3) gene
were amplified and sequenced in 33 fragments using
tumor DNA as previously demonstrated [19]. Primers
were designed using Primer 3 software [20] to cover at
least 20 base pairs at each 5’ and 3’ side of the exons.
The amplified DNA fragments were sequenced by using
the BigDye Terminator Cycle Sequencing kit on an ABI
3500xl DNA Analyzer (Applied Biosystems, Foster City,
CA, USA). Sequencing chromatograms generated by the
analyzer were examined for variant detection using Muta-
tion Surveyor software (SoftGenetics LLC., State College,
PA, USA).
Statistical methods for correlative analyses
The P values quoted for Figures 1, 2, and 3A were ob-
tained by applying the Wilcoxon test to all pairs within
the figure and correcting the resulting P values for mul-
tiple hypothesis testing using the Holm method [16].
Cell culture and pharmacologic inhibition assay
All cell lines were obtained and maintained as previously
described [21]. Independent pharmacologic inhibition
assays were conducted in triplicate for each cell line.
Cells were seeded at 20,000 per well in a 24-well plate.
After 24 hours, cells were treated in triplicate with indi-
cated concentrations of: DMSO, temozolomide (T2577,
Sigma-Aldrich, St Louis, MO, USA), or AZD-2281 (S1060,
Selleck Chemicals, Houston, TX, USA). After five days of
incubation, cells were fixed in 4% formaldehyde and
stained with 1% Crystal Violet (C0775, Sigma-Aldrich) for
10 minutes at room temperature. Cells were then washed
to remove unincorporated dye and plates were inverted to
dry overnight. Incorporated dye was extracted with 10%
acetic acid and OD595 measurements were obtained
within a linear range. Treated cells were normalized to the
vehicle-treated control to obtain mean percentage viability.
Figure 1 BD-L metagene values in primary and metastatic
specimens. Values in primary breast cancer and metastatic breast
cancer samples as calculated from a previously described cohort
detailed in Zhang et al. [29]. (A) Dot plot of individual metagene
values. (B) Box plot of metagene values. Statistically significant
differences in BD-L metagene value were observed for the brain
metastases when compared to primary tumors (P value=0.0043), bone
metastases (P value=4 ×10
−6) ,a n dl u n gm e t a s t a s e s( P value=0.001).
BD-L, BRCA1 Deficient-Like.
Figure 2 BD-L metagene values in sporadic and familial BRCA1
and BRCA2 primary tumors. BRCA1 metagene values in primary
sporadic breast cancer and BRCA1 and BRCA2 primary breast cancer
samples as calculated from a previously described cohort detailed in
van’t Veer et al. [30]. (A) Dot plot of individual metagene values.
(B) Box plot of metagene values. A statistically significant
difference in BD-L metagene value was observed for sporadic
primary breast tumors when compared to mutant BRCA1 carrier
primary breast tumors (P value=0.033). BD-L, BRCA1 Deficient-Like.
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To identify gene expression patterns that differentiate
HER2+ breast cancer brain metastases from HER2+ pri-
mary tumors that did not metastasize to the brain, we
performed a comparative gene expression analysis be-
tween 19 brain metastasis specimens from breast cancer
patients with the brain as a first-site metastasis and 19
non-patient-matched primary breast tumor specimens
from patients who either did not experience a relapse
(with minimum follow-up time of >6 years) or did not
have a recurrence in the central nervous system. None of
the patients with a brain metastasis received herceptin;
four of the patients without a relapse received neoadjuvant
or adjuvant herceptin. These specimens were matched
based upon the age of patient at initial detection, and the
HER2 and ER status of the primary tumors (Additional
file 1). Although patient-matched primary tumors were
not available for comparative gene expression analysis, we
hypothesized that the direct comparison of brain metasta-
ses to non-patient-matched primary tumors would pro-
vide insight into the key molecular pathways underlying
outgrowth in the brain microenvironment.
To compare gene expression, RNA derived from mi-
crodissected tissue was hybridized to Affymetrix X3P
GeneChips and the resulting data was subjected to bio-
informatic analyses. Standard MAS5 pre-processing of
the data with a t-test comparison and a false discovery
rate set at 0.25 failed to identify individually differentially
expressed genes between the brain metastatic specimens
and the non-patient-matched primary breast cancer
specimens.
As no significant differential expression for individual
genes was discovered, a GSEA using version 2.5 the
Broad Institute MSigDB was conducted to determine
if there were modulations of gene sets that comprise
annotated biochemical pathways [22]. The analysis yielded
22 enriched gene sets with a false discovery rate of q
value <0.25 (Additional file 1). The top gene set identi-
fied was BRCA1_OVEREXP_DN, which is comprised of
probe sets that were downregulated by two- to four-
fold after inducible expression of BRCA1 in the BRCA1-
low, ER+EcR-293 human embryonal kidney epithelial cell
line [23]. A significant correlation of the HER2+ breast
cancer brain metastases with a BRCA1-related signature
Figure 3 Distribution of BD-L value by ER and HER2 status. Dot
plot and box plot distribution of BD-L metagene values by ER and
HER2 status and correlation with clinical outcome in the (A) NKI295,
(B) EMC286/MSK82, and (C) EMC192 cohorts. Statistically significant
differences in BD-L metagene values were observed for ER-/HER- primary
tumors when compared to ER+/HER2+ (P value = (A) 4.5×10
−6, (B)
0.0025, (C) 2.8×10
−5)a n dE R + / H E R 2 -( P value=(A) 1.1×10
−13, (B)
4×10
−8, (C) 8.7×10
−10) subgroups. BD-L, BRCA1 Deficient-Like;E R ,
estrogen receptor; HER2, human epidermal growth factor receptor 2.
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quency of HER2 expression in tumors of BRCA1 mutation
carriers [24-26], and thus may reflect more upon the
underlying biology of metastatic outgrowth in the brain
rather than an aspect of HER2 signaling. Furthermore,
sequencing analysis for 17 of the 19 HER2+ brain
metastatic specimens for which sufficient residual tumor
remained identified no previously known pathogenic or
novel potentially pathogenic variants (Frameshift inser-
tion/deletion, nonsense or essential splicing site variants)
as classified by International Agency for Research on
Cancer (IARC) recommendations [27]. As our identi-
fied signature consisted of genes that were downregu-
lated when BRCA1 was overexpressed, we hypothesized
that the converse upregulation of these genes may indicate
an underlying deficiency in the BRCA1 functional path-
way, either directly through BRCA1 or indirectly through
a cooperating factor. Since the BRCA1_OVEREXP_DN
signature was enriched in HER2+ breast cancer brain me-
tastases that did not have known or potentially novel
BRCA1 pathogenic variants, we designated the BRCA1_O-
VEREXP_DN signature as the ‘BRCA1 Deficient-Like’
(BD-L) metagene. BD-L metagene values were calcu-
lated for each specimen, and significant association of
the metagene with the brain metastatic samples was
confirmed (Additional file 2, left panel; P value = 0.0082).
Additionally, a significant difference in BRCA1 expression
on the microarray between the primary tumors and
brain metastases was not observed for two probe sets
(Additional file 2, middle and right panel). Because
several of the brain metastasis samples were exhausted
during the previous analyses, a direct characterization
of BRCA1 mRNA and protein expression was prohib-
ited. However, a significant correlation between the
two BRCA1 probe sets on the Affymetrix X3P Gene-
Chip and the BD-L metagene was not observed for the
entire cohort, suggesting that metagene value may not
be merely tracking with BRCA1 mRNA expression
(Additional file 3). While BRCA1 protein expression
by IHC could not be examined, a previous study has
suggested significant concordance between BRCA1 mRNA
and protein expression in clinical specimens [28].
Although all patients in this cohort were confirmed to
have clinical 3+ HER2+ breast cancer by IHC and/or
fluorescent in situ hybridization (FISH), the possibility
existed that they were misclassified. To confirm overex-
pression of HER2 across the cohort, the expression
levels for all genes on the microarray were plotted on a
histogram and indicated genes were denoted for each
patient by a red line in Additional file 4. The expression
of HER2 showed a clear enrichment compared to PSA,
which is not reported to be highly expressed in breast
cancer, and PRY, DAZ4, and CDY1, which are all located
on chromosome Y and thus are not detected at high
levels in female breast cancer samples. Thus, the consist-
ently high level of HER2 expression across the cohort
supports the clinical HER2+ diagnosis.
To validate our original observation that the BD-L
metagene is enriched in breast cancer-derived brain me-
tastases, gene expression data from an independent co-
hort consisting of 615 primary breast cancer specimens
as well as breast cancer metastasis specimens from brain
(n =19), lung (n =18), liver (n = 5), and bone (n =15)
was assessed for correlation with BD-L [29]. As demon-
strated in Figure 1, a higher mean BD-L metagene value
was observed in metastases to the brain as compared
to primary tumors (P value= 0.0043), bone metastases
(P value=4 × 10
−6) ,a n dl u n gm e t a s t a s e s( P value =
0.001), but not when compared to liver (P value =
0.38). A limitation in using this data set is the re-
stricted number of metastatic samples in each group
and the lack of annotation of ER- and HER2-receptor
status for the metastatic data points. Given this limita-
tion, the significant association observed may support
the enrichment of the BD-L signature as being a feature of
brain metastases irrespective of receptor subtype.
Having confirmed an enrichment of BD-L metagene
value in brain metastases compared to primary tumors,
we then hypothesized that a metagene of BRCA1 defi-
ciency would also demonstrate increased values in pri-
mary tumor specimen derived from mutant BRCA1
carriers compared to noncarriers. When a publicly avail-
able gene expression data set was interrogated [30], a
significantly higher mean BD-L value was found in mu-
tant BRCA1 tumors (P value = 0.033) when compared to
sporadic tumors (Figure 2). While the BD-L value in pri-
mary tumors between sporadic breast cancer patients
and BRCA2 mutation carriers was not significant, there
is little power in the analysis given the small sample size
(n =2). The BD-L values for sporadic primary tumors in-
cluded a subset with elevated metagene values compar-
able to those of BRCA1 mutation carriers, which may be
indicative of a subpopulation of sporadic tumors with
characteristics similar to BRCA1 mutated tumors. The
correlation of the BD-L signature with both brain metas-
tases and BRCA1 mutation is consistent with the pub-
lished literature as BRCA1 mutation carriers are reported
to have an increased prevalence of breast cancer brain re-
lapse as compared to noncarriers [8,31].
To investigate the correlation of the BD-L metagene
with important molecular markers of sporadic breast
cancer subtypes, we next evaluated the distribution of
BD-L value by HER2 and ER status in the NKI295 [32],
EMC286 [33]/MSK82 [34], and EMC192 [35] cohorts of
sporadic primary tumors (Figure 3A-C). As BRCA1 mu-
tants represent a subpopulation within the triple nega-
tive breast cancer, an expected significantly higher BD-L
metagene mean value was observed in ER-/HER- primary
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values=4.5 × 10
−6 (NKI295), 0.0025 (EMC286/MSK82),
and 2.8 × 10
−5 (EMC192). Additionally, BD-L mean value
was significantly higher in ER-/HER- tumors when com-
pared and ER+/HER2- tumors, with P values=1.1 × 10
−13
(NKI295), 4 × 10
−8 (EMC286/MSK82), and 8.7 × 10
−10
(EMC192). Although not consistently significant across
the cohorts, a trend is observed when comparing ER-/
HER- tumors to ER-/HER2+ tumors, with P values=
0.0023 (NKI295), 0.097 (EMC286/MSK82), and 0.05
(EMC192). Despite the significant correlation with a
negative ER and/or HER2 receptor expression, it was
notable that a small subpopulation of tumors with high
BD-L values was present within the ER +and HER2+
subtypes (Figure 3A-C dot plots), suggesting that the
BD-L phenotype may extend beyond primary tumors
of BRCA1 mutation carriers and the sporadic ER-/
HER2- subtype. This is especially intriguing for pri-
mary ER +tumors because the brain is not a prevalent
metastatic site for the ER +subtype [36]. Motivated by
the possibility that the BD-L signature may extend
across current breast cancer classifications of receptor
expression or mutational status, we next sought to
apply the BD-L signature to breast cancer cell lines in-
dependent of receptor and mutational status with an
aim to identify a phenotype of pharmacological sensitivity.
We hypothesize that the BD-L metagene may identify
breast cancers that fall within a spectrum of dysfunction
for a BRCA1 functional complex or regulated pathway,
either directly through BRCA1 or indirectly through a
cooperating factor. Having demonstrated that BD-L was
enriched in BRCA1 mutation carriers, we hypothesized
that breast cancer cell lines with elevated BD-L values
may exhibit increased sensitivity to therapeutic agents
that target a dysfunctional BRCA1-associated pathway.
Poly (ADP-ribose) polymerase (PARP) inhibitors repre-
sent an exciting class of drugs that have demonstrated
promise in clinical BRCA1/2-related cancers as single
agents [37,38] and in preclinical studies as single agents
and in combination with certain classes of DNA-
damaging agents [39,40]. Additionally, preclinical test-
ing has revealed that disruption of proteins that cooperate
either directly or indirectly with BRCA1/2 proteins can in-
crease PARP inhibitor sensitivity [41-43]. Because we
hypothesize the BD-L metagene may correlate with a
spectrum of dysfunction, we chose to induce DNA dam-
age to enhance the effectiveness of the PARP inhibitor.
Therefore, we tested a panel of breast cancer cell lines for
sensitivity to a combination treatment with the PARP
inhibitor olaparib (AZD-2281), an oral PARP inhibitor
in clinical use that has shown evidence of crossing the
blood/brain barrier [44], and the DNA alkylating/
methylating agent temozolomide, a clinically utilized
chemotherapeutic that can cross the blood/brain barrier
and has demonstrated increased efficacy in combination
with a PARP inhibitor [45-48]. Using a publicly available
gene expression set, we determined BD-L metagene values
for 51 well-defined human breast cancer cell lines as
described in Neve et al. (Additional file 1) [21]. We
rank-ordered the lines by increasing metagene value,
and selected 12 cell lines predicted to be among either
the most resistant or most sensitive to pharmacologic
inhibition (Table 1). This panel included the BRCA1-
deficient HCC1937 cell line, which the BD-L metagene
predicts to exhibit low sensitivity. While this may ap-
pear paradoxical, clinical trials have demonstrated that
not all BRCA1 mutation carriers are responsive to
PARP inhibitors [37,38]. Additionally, Figure 2A dem-
onstrated that although the BD-L metagene is enriched
in BRCA1-mutation carriers compared to noncarriers,
as u b s e to fBRCA1 mutation carriers have low meta-
gene values. Because we hypothesize the BD-L meta-
gene provides a measure of a BRCA1-associated pathway
function rather than a BRCA1 gene mutation or the ex-
pression status, the metagene would also account for po-
tential compensatory mechanisms.
Based upon known mechanisms of temozolomide-
specific sensitivity and extensive in vitro pharmacological
studies in cell lines [49], 100 uM was determined to be a
physiologically relevant dose that does not demonstrate
significant reduction in viability across the breast cancer
cell line panel (Figure 4A, top panel). Single treatment and
combined treatment with temozolomide using increasing
sub-physiological doses of olaparib identified significant
Table 1 BRCA1 Deficient-Like (BD-L) distribution in a
breast cancer cell line panel
Cell line ER PR HER2 BRCA1 BD-L metagene value
HCC1143 - - - NA 207.2555
MDAMB415 + - - wt/- 208.6937
HCC1937 - - - m/- 226.181
BT20 - - - wt/- 227.6686
MDAMB468 - - - wt/- 260.2652
BT474 + + + wt/- 261.2111
HCC1428 + + - NA 265.375
MDAMB134VI + - - wt/wt 267.9736
SKBR3 - - + wt/- 277.6819
MCF10A - - - NA 285.3522
HCC1954 - - + NA 300.0448
HCC1500 - - - NA 300.3202
Breast cancer cell lines selected for pharmacological inhibition evaluation. BD-L
metagene values for the cell lines, as calculated from the Neve et al.[ 21] data
set, are listed by increasing value. Estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2) protein
expression status are indicated. If known, the BRCA1 mutational status is noted
(NA: not available).
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Additional file 5). As originally hypothesized, there is a
highly significant correlation (R
2=0. 77 ; P value 0.00017)
of the BD-L metagene with pharmacological response of
cell lines to the combined administration of olaparib and
temozolomide (Figure 4A, lower panel). It is interesting to
note that the metagene was able to correctly predict the
response of the BRCA1-deficient HCC1937 cell line, sug-
gesting the BD-L metagene may be a better indicator of
pharmacological response than BRCA1 gene status. To
further support the correlation with sensitivity, BD-L
metagene values were calculated for seven of the tested
cell lines from an independent gene expression data set
described in Garnett et al. [50] and was plotted using
our experimentally derived pharmacological response data.
While single administration of either temozolomide or
olaparib alone (Figure 4B, top and middle panel) did not
demonstrate a significant reduction in viability, a signifi-
cant correlation (R
2=0. 69 ;P value 0.02) is observed upon
dual administration and supports our original observation
(Figure 4B, lower panel). Thus, using two independent
gene expression data sets of cell lines derived from different
microarray platforms, the BD-L metagene demonstrated a
strong correlation with our experimentally derived DNA
damage-induced PARP inhibitor sensitivity.
To determine the robustness of BD-L metagene in
predicting sensitivity, we evaluated the performance of
five published signatures [30,51-53] of BRCA1/2 defi-
ciency and/or function in predicting our observed pharma-
cologic responses of the breast cancer cell line panel using
t h eg e n ee x p r e s s i o nd a t af r o mN e v eet al. [21] (Figure 4C,
A d d i t i o n a lf i l e6 A ,C ,E ,G )a n dG a r n e t tet al. [50]
( F i g u r e4 D ,A d d i t i o n a lf i l e6 B ,D ,F ,H ) .I nc o n t r a s tt o
the BD-L metagene (Figure 4A and B, bottom panels),
all five BRCA1/2-related signatures failed to correlate
with pharmacologic response (Figures 4C, D, Additional
file 6A-H). The difference in predictive power is poten-
tially due to the approach taken in discovering these sig-
natures. The BD-L metagene was derived from changes
in gene expression due to a modest overexpression of
BRCA1 within a single cell line. This unbiased approach
goes beyond indicating the BRCA1 mutational status or
the acute response to a stimulus to provide a measure
of BRCA1 pathway function that can include the contri-
bution of BRCA1 and its interacting components. Alter-
natively, the genes that comprise the BD-L metagene may
comprise functional networks that contribute to the
observed PARP inhibitor sensitivity. Mapping of the
112 BD-L genes to functional networks using Ingenuity
Pathway Analysis (IPA) identified a predominant network
Figure 4 Association of BD-L value with response to a combination of temozolomide and olaparib. Linear regression analyses of single
and combination treatment with 40 nM olaparib and 100 uM temozolomide using: (A,B) BD-L metagene values calculated using datasets from
(A) Neve et al. [21] and (B) Garnett et al. [50]; (C,D) BRCA1 breast cancer signature as described in van’t Veer et al. [30] calculated using data sets
from (C) Neve et al. and (D) Garnett et al. BD-L, BRCA1 Deficient-Like.
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cycle control, and apoptosis (Additional file 1). While
these functions have not previously been associated with
response to PARP inhibitors, the potential for specific as-
pects of these functions for influencing sensitivity provide
possible avenues for future investigation. In conclusion,
the BD-L metagene may provide a measure of BRCA1
pathway function as opposed to indicating BRCA1 muta-
tional status, direct expression levels, or response to an
acute stimulus.
Conclusions
In summary, we identified a BRCA1 Deficient-Like meta-
gene that is enriched in HER2+ brain metastases when
compared with HER2+ primary tumors, and in an inde-
pendent data set confirmed the enrichment of the meta-
gene in brain metastases as compared to bone metastases,
lung metastases, and primary breast tumors. Furthermore,
we demonstrated that high BD-L metagene value is
enriched in, but not limited to, primary tumors of
BRCA1 mutation carriers and sporadic ER-/HER2- pa-
tients. When the BD-L signature is calculated for a breast
cancer cell line panel using gene expression from two in-
dependent data sets, the BD-L metagene correlates with
pharmacologic response to a combination treatment of
olaparib and a temozolomide. Lastly, we demonstrated
that the BD-L metagene outperforms extant classifiers of
BRCA1/2 status in predicting pharmacological response
to the drug combination in the breast cancer cell panel.
Since the clinical administration of PARP inhibitors is
still in its infancy, there is a crucial need to both identify
patients who will gain benefit from this class of drugs
and to develop biomarkers that predict clinical response.
Currently, BRCA1/2 status is the prevailing indicator of
potential PARP inhibitor sensitivity, although not all
BRCA1/2 breast cancers respond and there is preclinical
evidence to suggest that PARP inhibitors may hold bene-
fit in cancer populations beyond BRCA1/2 mutation car-
riers [54]. Herein, we provide evidence that the BD-L
metagene may be enriched in clinically detectable breast
cancer brain metastases and the metagene may implicate
sporadic breast cancers across the conventional receptor
and mutational status classifications that may benefit
from a PARP inhibitor-based therapy while also identify-
ing triple negative and BRCA1-mutant cancers that may
prove refractory to treatment.
Additional files
Additional file 1: Assorted Tables. 1. Cohort characteristics. 2. Probe
mapping by figure. 3. GSEA output. 4. Cell line panel BD-L values. 5. IPA
networks. 6. IPA bio functions.
Additional file 2: BD-L value distribution in the discovery cohort.
Wilcoxon tests of the BD-L metagene (left panel) and BRCA1 probe sets
(middle, right panels) for the primary tumors (primary) and brain
metastases (mets) of the HER2+ discovery cohort.
Additional file 3: Correlation of BRCA1 expression with BD-L values
for the discovery cohort. Pearson correlation of BD-L metagene values
and BRCA1 probe set values for all specimens of the HER2+ discovery
cohort.
Additional file 4: Distribution of select probe sets across the
discovery cohort. Histograms representing the distribution for the
highest differentially expressed probe across all samples in the HER2+
discovery cohort. Each plot highlights a specific gene probe set indicated
above the histogram, with each patient’s corresponding expression value
highlighted as a red line.
Additional file 5: Linear regression of BD-L by cell line viability
under increasing concentrations of olaparib. Linear regression
analyses of BD-L metagene value by percentage cell line viability
following administration of 100 uM temozolomide (TMZ) and indicated
concentrations of olaparib. BD-L metagene values for the respective cell
lines are calculated using a gene expression data set derived from Neve
et al. [21] (Table 1).
Additional file 6: Linear regression of published BRCA1/2-associated
signatures by cell line viability. Linear regression analyses of BRCA-related
signatures by percentage cell line viability following single and combination
treatment with 40 nM olaparib and 100 uM temozolomide. (A,B) BRCA1-related
ovarian cancer signature as described in Konstantinopoulous et al. [51]
calculated using data sets from (A) Neve et al. [21] and (B) Garnett et al.
[50]; (C,D) BRCA1-related breast cancer signature as described in Kote-Jarai
et al. [53] calculated using data sets from (C) Neve et al. and (D) Garnett
et al.; (E,F) BRCA1-related ovarian cancer signature as described in
Kote-Jarai et al. [52] calculated using data sets from (E) Neve et al.a n d
(F) Garnett et al.; (G,H) BRCA2-related ovarian cancer signature as described
in Kote-Jarai et al. [52] calculated using data sets from (E) Neve et al.a n d( F )
Garnett et al.
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